Soleno Therapeutics Provides PWS Launch Update at Biotech Summit

Company discusses commercial progress, reimbursement trends, and regulatory review in Europe for its Prader-Willi syndrome treatment.

Published on Feb. 16, 2026

Got story updates? Submit your updates here. ›

Executives from Soleno Therapeutics provided an update on the company's commercial launch of its Prader-Willi syndrome (PWS) treatment, including details on reimbursement dynamics, patient conversion rates, and adverse event profiles. The company also discussed its regulatory progress in Europe and plans for capital deployment.

Why it matters

Soleno's PWS treatment is the first approved therapy for the rare genetic disorder, which is characterized by insatiable hunger and other hormonal and behavioral issues. The company's update provides insight into the early commercial performance and market access challenges for this novel therapy.

The details

Soleno said its PWS treatment has been on the market for about three quarters and outlined its process for converting prescriber start forms into active, revenue-generating patients. The company noted some discontinuation is expected but said overall rates appear healthy for a rare disease setting. Management also discussed adverse events, titration, and reimbursement, indicating progress has been better than expected. Internationally, Soleno provided an update on its European regulatory review and commercial planning.

  • Soleno's PWS treatment has been on the market for about three quarters.
  • The company expects to receive Day 180 questions from the European Medicines Agency at the end of February 2026.

The players

Soleno Therapeutics

A clinical-stage biopharmaceutical company focused on developing therapies for rare and orphan diseases, including its lead candidate diazoxide choline controlled release (DCCR) for the treatment of Prader-Willi syndrome.

Jim Mackaness

Chief Financial Officer of Soleno Therapeutics.

Anish Bhatnagar

Executive at Soleno Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.